date,title,source
Oct-23-18,"IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018",GlobeNewswire
Nov-06-18,"Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors",GlobeNewswire
Nov-15-18,IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference,GlobeNewswire
Nov-16-18,"Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-20-18,IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer,GlobeNewswire
Nov-26-18,IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018,GlobeNewswire
Dec-10-18,IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivacs Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018,GlobeNewswire
Dec-13-18,IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress,GlobeNewswire
Jan-17-19,First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMVs DPX Delivery Platform in Ovarian Cancer Patients,GlobeNewswire
Jan-28-19,IMV to Present at 2019 BIO CEO & Investor Conference,GlobeNewswire
Jan-29-19,IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA,GlobeNewswire
Feb-28-19,IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares,GlobeNewswire
Mar-01-19,IMV Inc. Announces Pricing of Public Offering,GlobeNewswire
Mar-06-19,IMV Inc. Closes Previously Announced Public Offering,Business Wire
Mar-07-19,IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference,Business Wire
Mar-08-19,"IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019",Business Wire
Mar-11-19,IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares,Business Wire
Mar-12-19,IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019,Business Wire
Mar-21-19,IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs,Business Wire
Mar-25-19,IMV Inc. to Present at Two Upcoming Investor Conferences,Business Wire
Mar-26-19,Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivacs Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer,Business Wire
Apr-03-19,New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMVs Immunotherapy Program,Business Wire
Apr-04-19,IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference,Business Wire
Apr-16-19,IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update,Business Wire
Apr-18-19,IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors,Business Wire
Apr-26-19,"IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019",Business Wire
May-08-19,IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019,Business Wire
May-09-19,IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances,Business Wire
May-10-19,IMV Announces Annual and Special Meeting of Shareholders Voting Results,Business Wire
May-14-19,IMV Inc. to Present at Upcoming Investor Conferences,Business Wire
